Abreu PD, Lacerda GÁJ, Romeu YSE, Miranda AC, González RL, Oria RN

Language: Spanish
References: 27
Page:
PDF size: 142.23 Kb.

ABSTRACT

A descriptive and retrospective study of all pediatric patients who were admitted on the pediatric intensive care unit suffering a severe head trauma was carried out from January 2003 to January 2012. After been controlled the intracranial hypertension and associated pathologies between 15 and 21 days, methylphenidate was administered to improve the wakefulness state. The universe was composed by 20 cases and the sample 13. It was begun with a minimum dose that was increased until obtaining the wished answer. Masculine sex predominated and the age group between 6 and 11 years. 62 patients presented a Glasgow Coma Scale of 8 points to the entrance, the greater number did not suffer previous diseases to the event (11) and 76.9% of them presented prevoius symptomatology to medicine administration. Within the most observed symptoms with its use it is the anxiety in 46.2%, followed by the slight arterial hypertension and the tachycardia. The improvement of the wakefulness state appears between 3 and 7 days starting the treatment in 69.23% of cases, this one extends by 10 to 15 days. It was necessary a daily doses of 2 tablets to control the hypersomnia.

REFERENCES

1. Langlois J, Rutland W, Wald M. The epidemiology and impact of traumatic brain injury: a brief overview. J Head Trauma Rehabilit. 2006; 21(5):375-8.

2. Langlois J, Rutland W, Thomas K. Traumatic brain injury in the United States: Emergency Department visits, hospitalizations, and deaths. Atlanta: Centers for Disease Control and Prevention, National Center for Injury Prevention and Control; 2004.

3. Marchio P, Previgliano I, Goldini C, Murillo Cabezas F. Traumatismo craneoencefálico en la ciudad de Buenos Aires: estudio epidemiológico prospectivo de base poblacional. Neurocirugía. 2006; 17:14-22.

4. Pradilla G, Vesga B, Leon F, Bautista L, Núñez LC, Vesga E, et al. Neuroepidemiología en el oriente colombiano. Rev Neurol. 2002; 34(11):1035-43.

5. Ríos-Romenets S, Castaño-Monsalve B, Bernabeu-Guitart M. Farmacoterapia de las secuelas cognitivas secundarias a traumatismo craneoencefálico. Rev Neurol. 2007; 45(9): 563-70.

6. Labi MC. Tratamiento neurofarmacológico tras un traumatismo craneoencefálico. Rehabilitación (Madr). 2002; 36(6):364-72.

7. Ressler KJ, Nemeroff CB. Role of norepinephrine in the pathophysiology if neuropsychiatric disorders. CNS Spectrums. 2001; 6:663-70.

8. Flanagan SR. Psychostimulant treatment of stroke and brain injury. CNS Spectrums. 2000; 5: 59-69.

9. Volkow ND, Wang GJ, Fowler JS, Logan J, Gerasimov M, Maynard L, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosc. 2001; 21:RC121.

10. Orient López F, Terre Boliart R, Bernabeu Guitart M, Ramón Rona S, Pérez Miras A. Utilidad de los fármacos dopaminérgicos en el daño cerebral de origen traumático. Rev Neurol. 2002; 35(4): 362-366.

11. Arciniegas DB, Silver JM. Pharmacotherapy of posttraumatic cognitive impairments. Behav Neurol. 2006; 17: 25-42.

12. Willmott C, Ponsford J. Efficacy methylphenidate in the rehabilitation of attention following traumatic brain injury: a randomized, crossover, double blind, placebo, controlled inpatiend trial. J Neurol Neurosurg Psychiatr. 2009; 80(5):552-7.

13. Siddall OM. Review. Use of methylphenidate in traumatic brain injury. Ann Pharmacoth. 2005; 39(7-8):1309-13.

14. Sneider WM, Drew-Cates J, Wong TM, Dowbovy LM. Cognitive and behavioural efficacy of Amantadine in acute traumatic brain injury: an initial doble blind placebo controlled study. Brain Injury. 1999:13(11): 863-72.

15. Meythaler JM, Brunners RC, Johnson A, Novack TA. Amantadine to improve neurorecovery in traumatic brain injury-associated diffuse axonal injury: a pilot double blind randomised trial. J Head Trauma Rehabilit. 2002; 17(4):300-13.

16. Watson N, Dikmen S, Machamer J, Doherty M, Temkin, N. Hypersomnia following traumatic brain injury. J Clin Sleep Med. 2007; 3(4): 363-368.

17. Castriotta R, Wilde M, Lai J, Atanasov S, Masel B, Kuna S. Prevalence and consequences of sleep disorders in traumatic brain injury. J Clin Sleep Med. 2007; 3(4):349-356.

18. Kim YM, Shin JC, An YC. Effects of methylphenidate on cerebral glucose metabolism in patients with imparien consciounsness. Clin Neuropharmacol. 2009; 32(6):335-9.

19. Gronborg P, Lijegren J, Jansen J.Paradoxical effect of methylphenidate in the treatment of a patient with severe traumatic injury. Ugeskr Laeger. 2009; 171(26):2201-2.

20. Willmott C, Ponsford J, Olver J, Ponsford M. Safety of methylphenidate following traumatic brain injury: impact on vital sign. J Rehabil Med. 2009; 41(7):585-7.

21. Challman TD, Lipsky JJ. Metylphenidate: its pharmacology and use. Mayo Clin Proc. 2000; 75:711-21.

22. Tagaya H. Methylphenidate: pharmacology, indication and potencial of abuse. Nihon Rinsho. 2010; 68(8):1550-5.

23. Taylor E, Dopfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, et al. European clinical guidelines for hyperkinetic disorder - first upgrade. Eur Child Adolesc Psychiatr. 2004; 13 Suppl1:I7-30.

24. Ministerio de Ciencia e Innovación. Guía de práctica clínica sobre el trastorno por déficit de atención con hiperactividad (TDAH) en niños y adolescentes. Barcelona: AIAQS; 2010.

25. Plenger PM, Dixon CE, Castillo RM. Subacute methylphenidate treatment for moderate severe traumatic brain injury: a preliminary double-blind placebo controlled study. Arch Phys Med Rehabilit. 1996; 77: 536-40.

26. Forsyth RJ, Jayamoni B, Paine TC. Agonistas monoaminérgicos para el traumatismo craneoencefálico agudo. Biblioteca Cochrane 2011; Número 1.

27. Willmott C, Ponsford J. Efficacy of methylphenidate in the rehabilitation of attention following tramatic brain injury: in rabdomiser, crossover, double blind, placebo controller. J Neurol Neurosurg Phychiatr. 2009; 80(5):552-7.